NM6603 / NucMito Pharma - LARVOL DELTA

A Phase 1 Study of NM6603 in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=17 | Terminated | Sponsor: NucMito Pharmaceuticals Co. Ltd. | N=36 ➔ 17 | Recruiting ➔ Terminated; Discontinuation based on a strategic sponsor decision, not driven by safety concerns.

Enrollment change • First-in-human • Trial termination • Oncology • Solid Tumor

Safety and Pharmacokinetics of NM6603 in Chinese Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: NucMito Pharmaceuticals Co. Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Colorectal Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Safety and Pharmacokinetics of NM6603 in Chinese Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: NucMito Pharmaceuticals Co. Ltd.

New P1 trial • Oncology • Solid Tumor

A Phase 1 Study of NM6603 in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: NucMito Pharmaceuticals Co. Ltd. | Trial completion date: Jul 2026 ➔ Feb 2026 | Trial primary completion date: Feb 2026 ➔ Oct 2025

Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Phase 1 Study of NM6603 in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: NucMito Pharmaceuticals Co. Ltd.

Metastases • New P1 trial • Gastrointestinal Cancer • Oncology • Solid Tumor